Search
Ulotaront
go.drugbank.com/drugs/DB15665InvestigationalSEP-363856 is a novel psychotropic drug being investigated for the treatment of schizophrenia. Unlike other drugs used for this condition, SEP-363856 does not bind to the dopamine D2 receptors, but exerts actions on the trace amine–assoc...
Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 SubstratesSelpercatinib
go.drugbank.com/drugs/DB15685ApprovedInvestigationalSelpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes. Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although mult...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesHomochlorcyclizine
go.drugbank.com/drugs/DB15979InvestigationalCategories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 Enzyme InhibitorsGarlic oil
go.drugbank.com/drugs/DB15989InvestigationalCategories: Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C9 InhibitorsFinerenone
go.drugbank.com/drugs/DB16165ApprovedInvestigationalFinerenone, or BAY 94-8862, is a mineralocorticoid receptor antagonist indicated to reduce the risk of sustained decline in glomerular filtration rate, end stage kidney disease, cardiovascular death, heart attacks, and hospitalization du...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 SubstratesPaltusotine
go.drugbank.com/drugs/DB16277ApprovedInvestigationalPaltusotine is a selective somatostatin receptor agonist: It mimics the biological actions of endogenous somatostatin, which activates the somatostatin 2 receptor (SST2) to block the secretion of growth hormone (GH) and decreases the pro...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesMobocertinib
go.drugbank.com/drugs/DB16390ApprovedInvestigationalWithdrawnMobocertinib is a kinase inhibitor targeted against human epidermal growth factor receptor (EGFR). It is used specifically in the treatment of non-small cell lung cancer (NSCLC) caused by exon 20 insertion mutations in the EGFR gene, whi...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsNaringin
go.drugbank.com/drugs/DB16859ExperimentalCategories: P-glycoprotein inhibitors, Cytochrome P-450 CYP3A InhibitorsCrinecerfont
go.drugbank.com/drugs/DB18518ApprovedInvestigationalPatients with congenital adrenal hyperplasia (CAH) face two major problems: adrenal insufficiency, caused by insufficient endogenous cortisol production, and androgen excess, caused by a counter-regulatory overproduction of adrenocortico...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 Substrates